Design of a pivotal phase III trial of allergen specific immunotherapy (AIT) using a high-dose house dust mite (HDM) allergoid in patients with allergic bronchial asthma

2018 ◽  
Author(s):  
Michael  Rudert ◽  
Viola Gödicke
Keyword(s):  
Bronchial Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Phase Iii ◽  
High Dose ◽  
Pivotal Phase ◽  
Allergen Specific Immunotherapy ◽  
Phase Iii Trial ◽  
Dust Mite

Allergen‐specific immunotherapy boosts allergen‐specific IgD production in house dust mite‐sensitized asthmatic patients

Allergy ◽  
2020 ◽  
Vol 75 (6) ◽  
pp. 1457-1460 ◽  
Author(s):  
Tadech Boonpiyathad ◽  
Panitan Pradubpongsa ◽  
Wat Mitthamsiri ◽  
Pattraporn Satitsuksanoa ◽  
Alain Jacquet ◽  
...  
Keyword(s):  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy ◽  
Asthmatic Patients ◽  
Dust Mite

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Allergen Specific Immunotherapy ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

IgG4 Antibodies in Patients with House-Dust-Mite-Sensitive Bronchial Asthma: Relationship with Antigen-Specific Immunotherapy

1983 ◽  
Vol 71 (2) ◽  
pp. 122-125 ◽  
Author(s):  
Takemase Nakagawa ◽  
Toshiaki Takaishi ◽  
Yoshio Sakamoto ◽  
Koji Ito ◽  
Terumasa Miyamoto ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Dust Mite
Sign in / Sign up

Export Citation Format

Share Document